Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG KWIKPEN versus HUMALOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG KWIKPEN versus HUMALOG MIX 50 50.
HUMALOG KWIKPEN vs HUMALOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake, glycogen synthesis, and lipogenesis, and inhibit gluconeogenesis and ketogenesis.
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
Subcutaneous injection of 0.2 to 0.6 units/kg/day divided into 3 or more doses, with the preprandial dose based on blood glucose monitoring. Typical total daily dose is 0.5 units/kg/day. Administer within 15 minutes before or after a meal.
None Documented
None Documented
Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation.
Subcutaneous injection: terminal half-life approximately 1-2 hours, reflecting clearance from the injection site and systemic elimination. Clinical context: allows twice-daily dosing.
Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine.
Primarily via renal excretion of insulin degradation products; less than 1% excreted as unchanged insulin. No significant biliary or fecal elimination.
Category C
Category C
Insulin
Insulin